Literature DB >> 10444204

Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia.

S H Otton, D L Turner, R Frewin, S V Davies, S A Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10444204     DOI： 10.1046/j.1365-2141.1999.01576.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

Review 1.  Autoimmune complications in chronic lymphocytic leukaemia (CLL).

Authors:  Clive S Zent; Neil E Kay
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

2.  Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.

Authors:  Steven P Treon; Jacob D Soumerai; Zachary R Hunter; Christopher J Patterson; Leukothea Ioakimidis; Brad Kahl; Michael Boxer
Journal:  Blood       Date:  2011-05-12       Impact factor: 22.113

Review 3.  Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.

Authors:  Anders Osterborg; Claes Karlsson; Jeanette Lundin
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

4.  Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).

Authors:  Sanford Kempin; Zhuoxin Sun; Neil E Kay; Elisabeth M Paietta; Joseph J Mazza; Rhett P Ketterling; Olga Frankfurt; David F Claxton; Joel N Saltzman; Gordan Srkalovic; Natalie S Callander; Gerald Gross; Martin S Tallman
Journal:  Acta Haematol       Date:  2019-07-23       Impact factor: 2.195

Review 5.  [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].

Authors:  C Warnke; B C Kieseier; U Zettl; H-P Hartung
Journal:  Nervenarzt       Date:  2009-04       Impact factor: 1.214

6.  Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Authors:  C L Hirst; A Pace; T P Pickersgill; R Jones; B N McLean; J P Zajicek; N J Scolding; N P Robertson
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

7.  BAFF is increased in renal transplant patients following treatment with alemtuzumab.

Authors:  D Bloom; Z Chang; K Pauly; J Kwun; J Fechner; C Hayes; M Samaniego; S Knechtle
Journal:  Am J Transplant       Date:  2009-06-12       Impact factor: 8.086
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.